ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, ...

Rebecca Grapevine breaks down Georgia legislation affecting access to HIV prevention medications and how pharmacies are ...

In this week's episode of the CNBC Changemakers and Power Players podcast, CNBC Senior Media and Tech Reporter Julia Boorstin spoke with Johanna Mercier, Chief Commercial & Corporate Affairs Officer ...

A single-pill treatment to suppress HIV proved as effective as existing therapies of up to 11 tablets daily, the latest advance in a scientific “golden age” for treating the virus even as rich ...

Merck said a treatment it is developing for HIV-1 met its primary endpoint in three Phase 3 trials. The biopharmaceutical company said Wednesday the results add to growing evidence for ...

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and ...

The science works. The system doesn't.

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.

Findings may reassure a population already at greater risk ...

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...

Tallahassee health officials have pushed through an emergency rule that would dramatically tighten who qualifies for ...

The state issued the emergency rule Tuesday night on the eve of an emergency hearing. The cuts to the AIDS Drug Assistance ...